Efficacy and tolerability of levetiracetam in children younger than 4 years: A retrospective review

M. Scott Perry, Michael G Benatar

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: To review our experience of the efficacy and tolerability of levetiracetam (LEV) in children younger than 4 years. Methods: We used retrospective chart review to identify 122 children with seizures who were younger than 4 years and followed for ≥6 months. Efficacy was evaluated on the basis of the occurrence and durability of seizure remission. Tolerability was based on parent- and patient-reported side effects. Results: Seventy (57%) subjects achieved seizure remission, and 52 (43%) did not. In univariate analysis, those achieving seizure remission were more likely to have partial epilepsy, require lower maintenance doses of LEV, and have fewer than two seizures per month at initiation of the medication. Only seizure frequency at initiation of LEV remained significant in multivariate analysis. The median duration of seizure freedom (8.9 months) was not influenced by age, epilepsy type, gender, or pretreatment seizure frequency. The dose of LEV was the only significant predictor of the duration of seizure remission, with longer duration of seizure remission seen in those taking <30 mg/kg/day compared with those taking >30 mg/kg/d (median, 12.8 months vs. 3 months; p < 0.0001). Side effects of LEV occurred in 34% of subjects but required discontinuation in only 16%, most commonly because of behavioral disturbances. Conclusions: LEV is an effective medication in children younger than 4 years and at doses lower than previously reported. It is also well tolerated, suggesting that it represents an important option for the treatment of epilepsy in this age group.

Original languageEnglish
Pages (from-to)1123-1127
Number of pages5
JournalEpilepsia
Volume48
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

etiracetam
Seizures
Epilepsy

Keywords

  • Children
  • Epilepsy
  • Levetiracetam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Efficacy and tolerability of levetiracetam in children younger than 4 years : A retrospective review. / Perry, M. Scott; Benatar, Michael G.

In: Epilepsia, Vol. 48, No. 6, 01.06.2007, p. 1123-1127.

Research output: Contribution to journalArticle

@article{32c6d52e27b0436784b12f25cce61ed1,
title = "Efficacy and tolerability of levetiracetam in children younger than 4 years: A retrospective review",
abstract = "Purpose: To review our experience of the efficacy and tolerability of levetiracetam (LEV) in children younger than 4 years. Methods: We used retrospective chart review to identify 122 children with seizures who were younger than 4 years and followed for ≥6 months. Efficacy was evaluated on the basis of the occurrence and durability of seizure remission. Tolerability was based on parent- and patient-reported side effects. Results: Seventy (57{\%}) subjects achieved seizure remission, and 52 (43{\%}) did not. In univariate analysis, those achieving seizure remission were more likely to have partial epilepsy, require lower maintenance doses of LEV, and have fewer than two seizures per month at initiation of the medication. Only seizure frequency at initiation of LEV remained significant in multivariate analysis. The median duration of seizure freedom (8.9 months) was not influenced by age, epilepsy type, gender, or pretreatment seizure frequency. The dose of LEV was the only significant predictor of the duration of seizure remission, with longer duration of seizure remission seen in those taking <30 mg/kg/day compared with those taking >30 mg/kg/d (median, 12.8 months vs. 3 months; p < 0.0001). Side effects of LEV occurred in 34{\%} of subjects but required discontinuation in only 16{\%}, most commonly because of behavioral disturbances. Conclusions: LEV is an effective medication in children younger than 4 years and at doses lower than previously reported. It is also well tolerated, suggesting that it represents an important option for the treatment of epilepsy in this age group.",
keywords = "Children, Epilepsy, Levetiracetam",
author = "Perry, {M. Scott} and Benatar, {Michael G}",
year = "2007",
month = "6",
day = "1",
doi = "10.1111/j.1528-1167.2007.01003.x",
language = "English",
volume = "48",
pages = "1123--1127",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy and tolerability of levetiracetam in children younger than 4 years

T2 - A retrospective review

AU - Perry, M. Scott

AU - Benatar, Michael G

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Purpose: To review our experience of the efficacy and tolerability of levetiracetam (LEV) in children younger than 4 years. Methods: We used retrospective chart review to identify 122 children with seizures who were younger than 4 years and followed for ≥6 months. Efficacy was evaluated on the basis of the occurrence and durability of seizure remission. Tolerability was based on parent- and patient-reported side effects. Results: Seventy (57%) subjects achieved seizure remission, and 52 (43%) did not. In univariate analysis, those achieving seizure remission were more likely to have partial epilepsy, require lower maintenance doses of LEV, and have fewer than two seizures per month at initiation of the medication. Only seizure frequency at initiation of LEV remained significant in multivariate analysis. The median duration of seizure freedom (8.9 months) was not influenced by age, epilepsy type, gender, or pretreatment seizure frequency. The dose of LEV was the only significant predictor of the duration of seizure remission, with longer duration of seizure remission seen in those taking <30 mg/kg/day compared with those taking >30 mg/kg/d (median, 12.8 months vs. 3 months; p < 0.0001). Side effects of LEV occurred in 34% of subjects but required discontinuation in only 16%, most commonly because of behavioral disturbances. Conclusions: LEV is an effective medication in children younger than 4 years and at doses lower than previously reported. It is also well tolerated, suggesting that it represents an important option for the treatment of epilepsy in this age group.

AB - Purpose: To review our experience of the efficacy and tolerability of levetiracetam (LEV) in children younger than 4 years. Methods: We used retrospective chart review to identify 122 children with seizures who were younger than 4 years and followed for ≥6 months. Efficacy was evaluated on the basis of the occurrence and durability of seizure remission. Tolerability was based on parent- and patient-reported side effects. Results: Seventy (57%) subjects achieved seizure remission, and 52 (43%) did not. In univariate analysis, those achieving seizure remission were more likely to have partial epilepsy, require lower maintenance doses of LEV, and have fewer than two seizures per month at initiation of the medication. Only seizure frequency at initiation of LEV remained significant in multivariate analysis. The median duration of seizure freedom (8.9 months) was not influenced by age, epilepsy type, gender, or pretreatment seizure frequency. The dose of LEV was the only significant predictor of the duration of seizure remission, with longer duration of seizure remission seen in those taking <30 mg/kg/day compared with those taking >30 mg/kg/d (median, 12.8 months vs. 3 months; p < 0.0001). Side effects of LEV occurred in 34% of subjects but required discontinuation in only 16%, most commonly because of behavioral disturbances. Conclusions: LEV is an effective medication in children younger than 4 years and at doses lower than previously reported. It is also well tolerated, suggesting that it represents an important option for the treatment of epilepsy in this age group.

KW - Children

KW - Epilepsy

KW - Levetiracetam

UR - http://www.scopus.com/inward/record.url?scp=34249799027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249799027&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2007.01003.x

DO - 10.1111/j.1528-1167.2007.01003.x

M3 - Article

C2 - 17430408

AN - SCOPUS:34249799027

VL - 48

SP - 1123

EP - 1127

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 6

ER -